Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    Immunogenicity and reactogenicity of concomitantly administered hexavalent and Group B meningococcal vaccines in infancy.

    Summary
    EudraCT number
    2018-003451-38
    Trial protocol
    GB  
    Global end of trial date
    22 Feb 2022

    Results information
    Results version number
    v1(current)
    This version publication date
    10 Sep 2022
    First version publication date
    10 Sep 2022
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    OVG2018/05
    Additional study identifiers
    ISRCTN number
    ISRCTN85819697
    US NCT number
    -
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Oxford Vaccine Group
    Sponsor organisation address
    Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Headington, Oxford, Oxford, United Kingdom, OX3 7LE
    Public contact
    Professor Matthew Snape, Oxford Vaccine Group, +44 01865611400, matthew.snape@paediatrics.ox.ac.uk
    Scientific contact
    Professor Matthew Snape, Oxford Vaccine Group, +44 01865611400, matthew.snape@paediatrics.ox.ac.uk
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    25 Feb 2022
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    09 Apr 2021
    Global end of trial reached?
    Yes
    Global end of trial date
    22 Feb 2022
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    To compare the immune response of the Haemophilus influenza type B (Hib) component of the 6in1-IH (Infanrix-Hexa) and 6in1-V (Vaxelis) vaccines when co-administered with 4CMenB in the UK routine immunisation schedule, as measured by blood tests taken at at 5 months of age.
    Protection of trial subjects
    All participants received an approved, routine vaccine in a location convenient to them. Anaesthetic cream, to numb the skin, was provided before the blood samples at 5 and 13 months were taken. Participants parents were also provided with telephone access to an on-call study team member for urgent clinical queries related to the trial. Any stress and discomfort is also reduced by using distraction techniques and play assistants accompanying clinical staff on visits.
    Background therapy
    All participants in both groups received: Bexsero (MenB) at 2, 4 and 12 months of age Rotarix (Rotavirus) orally at 2 and 3 months of age Prevenar13 (PCV13) at 3 and 12 months of age Menitorix (Hib/MenC) at 12 months of age MMR VaxPro or Priorix at 12 months of age
    Evidence for comparator
    The study compared the concentrations of antibodies against Haemophilus influenza type B in response to immunisation with either Vaxelis or Infanrix-hexa, to determine if Vaxelis could be used in the UK immunisation schedule alongside 4CMenb (Bexsero). Having the option to use either of the 6 in 1 vaccines is important to ensure all children continue to be immunised even if one vaccine becomes temporarily unavailable.
    Actual start date of recruitment
    16 Jul 2019
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    United Kingdom: 194
    Worldwide total number of subjects
    194
    EEA total number of subjects
    0
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    194
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    0
    From 65 to 84 years
    0
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    Parents/legal guardians of potential participants were informed of the study through website based advertising and social media. The main method of recruitment, mailouts through National Health Applications and Infrastructure Services who hold the central NHS patient database and the Child Health Information Service an equivalent NHS database.

    Pre-assignment
    Screening details
    Participants were screened over the phone to conduct an eligibility check. Then during the first visit, participant’s eligibility was assessed by a study doctor after medical history was taken and examination performed. A total of 86 participant were excluded (Living out of area, language barriers and having already had 8 week immunisations).

    Period 1
    Period 1 title
    Overall Trial (Overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Group 1
    Arm description
    Group 1 received the routine schedule of Infanrix Hexa at 2, 3 and 4 months. Both groups then received Meningococcal B at 2, 4 and 12 months. Rotavirus at 2 and 3 months. PCV13 at 3 and 12 months. With a Hib-MenC and MMR vaccine at 12 months.
    Arm type
    Active comparator

    Investigational medicinal product name
    6 in1 (IH) (Infanrix hexa)
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Suspension for injection
    Routes of administration
    Injection , Intramuscular use
    Dosage and administration details
    It is available as a powder and suspension for intramuscular injection with a volume of 0.5ml. It can be given as a 3 dose primary series on the current UK immunisation schedule

    Investigational medicinal product name
    Meningococcal B
    Investigational medicinal product code
    Other name
    Bexsero
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Injection , Intramuscular use
    Dosage and administration details
    4-component Meningococcal B (4CMenB) vaccine IM 0.5ml given at 2, 4 and 12 months

    Investigational medicinal product name
    Rotavirus
    Investigational medicinal product code
    Other name
    Rotarix
    Pharmaceutical forms
    Oral suspension in pre-filled oral applicator
    Routes of administration
    Oral use
    Dosage and administration details
    Rotavirus vaccine oral 1.5ml at 2 and 3 months

    Investigational medicinal product name
    PCV13
    Investigational medicinal product code
    Other name
    Prevenar13
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Injection , Intramuscular use
    Dosage and administration details
    13 valent pneumococcal conjugate vaccine (PCV13) IM 0.5ml, administered at 3 and 12 months, in line with the routine UK infant immunisation schedule for infants born on or after 1 January 2020.

    Investigational medicinal product name
    Meningococcal C/Hib vaccine
    Investigational medicinal product code
    Other name
    Menitorix
    Pharmaceutical forms
    Powder and solvent for solution for injection in cartridge
    Routes of administration
    Injection , Intramuscular use
    Dosage and administration details
    Meningococcal C/Hib vaccine IM 0.5ml at 12 months

    Investigational medicinal product name
    Measles/Mumps/Rubella (MMR) vaccine
    Investigational medicinal product code
    Other name
    MMR VaxPro or Priorix
    Pharmaceutical forms
    Powder and solvent for solution for injection in pre-filled syringe
    Routes of administration
    Injection , Intramuscular use
    Dosage and administration details
    Measles/Mumps/Rubella (MMR) vaccine IM 0.5ml at 13 months

    Arm title
    Group 2
    Arm description
    Group 2 were also vaccinated following the routine UK infant immunisation schedule, however they were administered 6in1 - Vaxelis rather than Infanrix Hexa. They then also received the additional vaccines: Meningococcal B at 2, 3 and 12 months. Rotavirus at 2 and 3 months. PCV13 at 3 and 12 months. With a Hib-Men C and MMR vaccine at 12 months.
    Arm type
    Active comparator

    Investigational medicinal product name
    6 in1 (IH) (Infanrix hexa)
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Suspension for injection
    Routes of administration
    Injection , Intramuscular use
    Dosage and administration details
    It is available as a powder and suspension for intramuscular injection with a volume of 0.5ml. It can be given as a 3 dose primary series on the current UK immunisation schedule

    Investigational medicinal product name
    Meningococcal B
    Investigational medicinal product code
    Other name
    Bexsero
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Injection , Intramuscular use
    Dosage and administration details
    4-component Meningococcal B (4CMenB) vaccine IM 0.5ml given at 2, 4 and 12 months

    Investigational medicinal product name
    Rotavirus
    Investigational medicinal product code
    Other name
    Rotarix
    Pharmaceutical forms
    Oral suspension in pre-filled oral applicator
    Routes of administration
    Oral use
    Dosage and administration details
    Rotavirus vaccine oral 1.5ml at 2 and 3 months

    Investigational medicinal product name
    PCV13
    Investigational medicinal product code
    Other name
    Prevenar13
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Injection , Intramuscular use
    Dosage and administration details
    13 valent pneumococcal conjugate vaccine (PCV13) IM 0.5ml, administered at 3 and 12 months, in line with the routine UK infant immunisation schedule for infants born on or after 1 January 2020.

    Investigational medicinal product name
    Meningococcal C/Hib vaccine
    Investigational medicinal product code
    Other name
    Menitorix
    Pharmaceutical forms
    Powder and solvent for solution for injection in cartridge
    Routes of administration
    Injection , Intramuscular use
    Dosage and administration details
    Meningococcal C/Hib vaccine IM 0.5ml at 12 months

    Investigational medicinal product name
    Measles/Mumps/Rubella (MMR) vaccine
    Investigational medicinal product code
    Other name
    MMR VaxPro or Priorix
    Pharmaceutical forms
    Powder and solvent for solution for injection in pre-filled syringe
    Routes of administration
    Injection , Intramuscular use
    Dosage and administration details
    Measles/Mumps/Rubella (MMR) vaccine IM 0.5ml at 13 months

    Number of subjects in period 1
    Group 1 Group 2
    Started
    98
    96
    Completed
    91
    89
    Not completed
    7
    7
         Moved out of area
    3
    3
         Consent withdrawn by subject
    3
    3
         Recruited to another study
    -
    1
         Lost to follow-up
    1
    -

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Group 1
    Reporting group description
    Group 1 received the routine schedule of Infanrix Hexa at 2, 3 and 4 months. Both groups then received Meningococcal B at 2, 4 and 12 months. Rotavirus at 2 and 3 months. PCV13 at 3 and 12 months. With a Hib-MenC and MMR vaccine at 12 months.

    Reporting group title
    Group 2
    Reporting group description
    Group 2 were also vaccinated following the routine UK infant immunisation schedule, however they were administered 6in1 - Vaxelis rather than Infanrix Hexa. They then also received the additional vaccines: Meningococcal B at 2, 3 and 12 months. Rotavirus at 2 and 3 months. PCV13 at 3 and 12 months. With a Hib-Men C and MMR vaccine at 12 months.

    Reporting group values
    Group 1 Group 2 Total
    Number of subjects
    98 96 194
    Age categorical
    Units: Subjects
        In utero
    0 0 0
        Preterm newborn infants (gestational age < 37 wks)
    0 0 0
        Newborns (0-27 days)
    0 0 0
        Infants and toddlers (28 days-23 months)
    98 96 194
        Children (2-11 years)
    0 0 0
        Adolescents (12-17 years)
    0 0 0
        Adults (18-64 years)
    0 0 0
        From 65-84 years
    0 0 0
        85 years and over
    0 0 0
    Age continuous
    Age at first Infanrix Hexa/Vaxelis dose
    Units: days
        median (full range (min-max))
    60 (57.2 to 63) 60 (57 to 63) -
    Gender categorical
    Units: Subjects
        Female
    50 52 102
        Male
    48 44 92

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Group 1
    Reporting group description
    Group 1 received the routine schedule of Infanrix Hexa at 2, 3 and 4 months. Both groups then received Meningococcal B at 2, 4 and 12 months. Rotavirus at 2 and 3 months. PCV13 at 3 and 12 months. With a Hib-MenC and MMR vaccine at 12 months.

    Reporting group title
    Group 2
    Reporting group description
    Group 2 were also vaccinated following the routine UK infant immunisation schedule, however they were administered 6in1 - Vaxelis rather than Infanrix Hexa. They then also received the additional vaccines: Meningococcal B at 2, 3 and 12 months. Rotavirus at 2 and 3 months. PCV13 at 3 and 12 months. With a Hib-Men C and MMR vaccine at 12 months.

    Primary: Anti-PRP (Hib) IgG concentrations when co-administered with 4CMenB

    Close Top of page
    End point title
    Anti-PRP (Hib) IgG concentrations when co-administered with 4CMenB
    End point description
    Compare the immunogenicity of the Haemophilus influenza type B (Hib) component of 6 in 1(IH) (Infanrix hexa) and 6 in 1(V) (Vaxelis) when co-administered with 4CMenB in the UK routine immunisation schedule at 5 months of age. Assess the anti-PRP (Hib) IgG concentrations at 5 months of age as measured by ELISA.
    End point type
    Primary
    End point timeframe
    5 months of age
    End point values
    Group 1 Group 2
    Number of subjects analysed
    87
    85
    Units: U/ml
        geometric mean (confidence interval 95%)
    0.87 (0.66 to 1.16)
    20.34 (14.58 to 28.37)
    Statistical analysis title
    Statistical analyses title: Two-sided t-test
    Statistical analysis description
    Two-sided t-test for superiority of Hex-V compared to Hex-IH in anti-PRP IgG GMCs at 5 month of age
    Comparison groups
    Group 2 v Group 1
    Number of subjects included in analysis
    172
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    < 0.0001
    Method
    t-test, 2-sided
    Parameter type
    Geometric mean ratio
    Point estimate
    23.25
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    15.11
         upper limit
    35.78

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Solicited local and systemic adverse events post 5 days of any immunisation.
    Adverse event reporting additional description
    All AEs that occur within 5 days of a vaccination visit and all SAEs (excluding those defined in the protocol as not requiring reporting) that occur during the study that are observed by the Investigator or reported by the participant’s parent/guardian, will be recorded on the CRF, whether or not attributed to trial vaccines.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    Protocol
    Dictionary version
    V4.0
    Reporting groups
    Reporting group title
    Group 1
    Reporting group description
    Group 1 received the routine schedule of Infanrix Hexa at 2, 3 and 4 months. Both groups then received Meningococcal B at 2, 4 and 12 months. Rotavirus at 2 and 3 months. PCV13 at 3 and 12 months. With a Hib-MenC and MMR vaccine at 12 months.

    Reporting group title
    Group 2
    Reporting group description
    Group 2 were also vaccinated following the routine UK infant immunisation schedule, however they were administered 6in1 - Vaxelis rather than Infanrix Hexa. They then also received the additional vaccines: Meningococcal B at 2, 3 and 12 months. Rotavirus at 2 and 3 months. PCV13 at 3 and 12 months. With a Hib-Men C and MMR vaccine at 12 months.

    Serious adverse events
    Group 1 Group 2
    Total subjects affected by serious adverse events
         subjects affected / exposed
    7 / 98 (7.14%)
    9 / 96 (9.38%)
         number of deaths (all causes)
    0
    0
         number of deaths resulting from adverse events
    0
    0
    Injury, poisoning and procedural complications
    Head injury
    Additional description: Head injury and respiratory tract infection
         subjects affected / exposed
    0 / 98 (0.00%)
    1 / 96 (1.04%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Bronchiolitis
         subjects affected / exposed
    4 / 98 (4.08%)
    4 / 96 (4.17%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Viral infection
         subjects affected / exposed
    1 / 98 (1.02%)
    0 / 96 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Respiratory tract infection
         subjects affected / exposed
    0 / 98 (0.00%)
    2 / 96 (2.08%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Croup
         subjects affected / exposed
    0 / 98 (0.00%)
    1 / 96 (1.04%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Renal and urinary disorders
    Urinary tract infection with unilateral ureteric dilatation
         subjects affected / exposed
    0 / 98 (0.00%)
    1 / 96 (1.04%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Infections and infestations
    Pyrexia
    Additional description: Post immunisation fever
         subjects affected / exposed
    1 / 98 (1.02%)
    0 / 96 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Tonsillitis
    Additional description: Tonsillitis and gastro-esophageal reflux disease
         subjects affected / exposed
    1 / 98 (1.02%)
    0 / 96 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 0%
    Non-serious adverse events
    Group 1 Group 2
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    96 / 98 (97.96%)
    96 / 96 (100.00%)
    General disorders and administration site conditions
    Irritability
         subjects affected / exposed
    91 / 98 (92.86%)
    94 / 96 (97.92%)
         occurrences all number
    91
    94
    Drowsiness
         subjects affected / exposed
    84 / 98 (85.71%)
    82 / 96 (85.42%)
         occurrences all number
    84
    82
    Change in appetite/feeding
         subjects affected / exposed
    74 / 98 (75.51%)
    73 / 96 (76.04%)
         occurrences all number
    74
    73
    Fever
    Additional description: Fever ≥ 37.6°C
         subjects affected / exposed
    47 / 98 (47.96%)
    38 / 96 (39.58%)
         occurrences all number
    47
    38
    Gastrointestinal disorders
    Diarrhoea
         subjects affected / exposed
    63 / 98 (64.29%)
    66 / 96 (68.75%)
         occurrences all number
    63
    66
    Vomiting
         subjects affected / exposed
    53 / 98 (54.08%)
    52 / 96 (54.17%)
         occurrences all number
    53
    52

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    25 Apr 2019
    Edits made to the Protocol, Participant Information booklet and the Health Professional Letter to reflect a change in immunisation schedule for the Pneumococcal conjugate vaccine (PCV)13. This vaccine will be administered at 3 and 12 months rather than at 2, 4 and 12 months as is routinely given. This anticipated change in UK infant immunisation schedule is planned for 2019 (see attached cover letter for additional details). IMP name error in the Initial IRAS form submission One of the investigational medicinal product (IMP) for this study is 6 in 1(IH) (Infanrix hexa) vaccine which protects against diphtheria, tetanus, poliovirus, whooping cough (pertussis), hepatitis B and haemophilus influenza B (Hib). We have however noted that in the IMP section of the initial IRAS application form that was submitted, in error we wrote and described the components of the 5in1 vaccine (commercially known as INFANRIX-IPV+Hib, which does not contain the Hepatitis B component) instead of Infanrix Hexa
    22 Jul 2019
    Amendments to an existing REC approved documents: Ametop and EMLA Instructions (over 1 year) documents using revised and updated templates, Recruitment Text To request addition of new study documents: EMLA Instructions 3 months - 11 months EMLA Instructions Animation Video EMLA Instructions Animation Script
    06 Jan 2020
    Protocol amendment: -Change of wording of sentence regarding PCV13 administration timings from ‘This reflects the imminent change in the UK infant immunisation schedule’ to ‘This reflects the change in the routine UK infant immunisation schedule for infants born on or after 1 January 2020.’ - Change in wording of a sentence in Section 8.6 to clarify when finger or heel prick would be appropriate to attempt if venepuncture is unsuccessful in participants. Participant Information Booklet - Change of wording of sentence regarding PCV administration timings from “*PCV 13 will be administered at 3 and 12 months, instead of 2, 4 and 12 months as routinely given at the time of the study start date (May 2019). This reflects a change in the UK infant immunisation schedule planned for 2019.” To “*PCV 13 will be administered at 3 and 12 months, this reflects the change in the routine UK infant immunisation schedule for infants born on or after 1 January 2020.” To request addition of new study document: - Parent PCV13 Update Letter
    17 Aug 2020
    Adjusted sample size and power calculations changes on the study protocol: After reviewing the current disruption on clinical activities by COVID-19 and the urgency to obtain the data for policy making in the UK, the study team decided to evaluate the study power based on the recruitment up to the time this was paused for the COVID-19 pandemic, and decided to increase the type I error from two-sided 5% (one-sided 2.5%) to one-sided 5%. The current study recruitment has achieved the planned power based on the adjusted type I error. Therefore, the study CI, sponsor and funder group has decided not to resume recruiting and continue with a sample size of 194 participants.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    Recruitment paused due to the COVID-19 pandemic, the current study recruitment (194) had achieved the planned power based on the adjusted type I error. Secondary objectives and results will be reported in the finalised publication in due course.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 13:39:21 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA